Clinical trial
Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder
NCT00252343 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00252343 |
|---|---|
| Title | Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder |
| Official title | An Eight-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Escitalopram (10mg qd) as Positive Control, Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Outpatients With Generalized Anxiety Disorder |
| Acronym | LIBRA |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anxiety Disorder |
| Intervention type | Drug |
| Interventions | SR58611A |
| Enrollment | 360 |
| Start date | Sep 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Nov 11, 2005 |
| Last update posted | Mar 12, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: